Research & development increased 91.5%
Research & development changed +91.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Research & development changed +91.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Stock-based compensation changed +42.2% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Operating income changed -139.7% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Net income changed -162.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Operating margin changed -50407 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Revenue changed -32.5% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
SBC / revenue changed +6085 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
Cash & equivalents changed +8.4% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.